Biotech Stocks on Investors' Radar -- Tesaro, Trevena, Omeros, and Radius Health

NEW YORK, October 13, 2017 /PRNewswire/ --

If you want a Stock Review on TSRO, TRVN, OMER, or RDUS then come over to and sign up for your free customized report. On Thursday, October 12, 2017, US markets saw five out of nine sectors finishing the day in red and four in green. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,591.51, down 0.18%; the Dow Jones Industrial Average edged 0.14% lower, to finish at 22,841.01; and the S&P 500 closed at 2,550.93, down 0.17%. This Friday morning, looks at the performance of these four Biotechnology stocks: Tesaro Inc. (NASDAQ: TSRO), Trevena Inc. (NASDAQ: TRVN) , Omeros Corp. (NASDAQ: OMER), and Radius Health Inc. (NASDAQ: RDUS). This morning's free research reports on the aforesaid equities can be accessed upon registration on at:


On Thursday, shares in Waltham, Massachusetts headquartered Tesaro Inc. recorded a trading volume of 460,074 shares. The stock ended the session 2.82% higher at $121.23. The Company's shares have gained 5.63% in the past twelve months. The stock is trading above its 50-day moving average by 0.19%. Moreover, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have a Relative Strength Index (RSI) of 52.61.

On October 12th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $158 per share. Visit us today and download your complete report on TSRO for free at:


King of Prussia, Pennsylvania headquartered Trevena Inc.'s stock closed the day 16.88% lower at $1.97. A total volume of 3.93 million shares was traded, which was above its three months average volume of 502.48 thousand shares. The stock is trading below its 50-day moving average by 19.94%. Additionally, shares of Trevena, which develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 24.48.

On October 12th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $8 a share to $7 a share. The complimentary research report on TRVN can be accessed at:


Shares in Seattle, Washington-based Omeros Corp. recorded a trading volume of 411,063 shares. The stock ended yesterday's trading session 2.86% lower at $20.37. The Company's shares have advanced 161.15% in the past twelve months and 105.34% on an YTD basis. The stock is trading above its 200-day moving average by 22.43%. Furthermore, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 39.63. Register for free on and download the research report on OMER at:

Radius Health 

Waltham, Massachusetts headquartered Radius Health Inc.'s stock finished Thursday's session 2.18% higher at $37.57 with a total trading volume of 658,078 shares. The Company's shares have advanced 11.02% in the last month. The stock is trading above its 50-day moving average by 1.86%. Additionally, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have an RSI of 53.61.

On October 06th, 2017, research firm Goldman resumed its 'Neutral' rating on the Company's stock. Get free access to your research report on RDUS at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.